EGFR and neoplasm: However, when it is overexpressed or abnormally activated, it can lead to tumour development and progression.EGFR is an important target that has been clearly identified that can be used in the treatment of colorectal cancer, and cetuximab is one of these important targeted agents [32], but its "endurance" in treatment is limited, and its continued use will not only reduce its effectiveness, but also cause side effects.